Daewoong Pharmaceutical Confirms Efficacy and Safety in Phase 3 Clinical Trial of Diabetes Treatment

[Asia Economy Reporter Minwoo Lee] Daewoong Pharmaceutical announced on the 14th that it has confirmed the efficacy and safety of the Phase 3 clinical trial results for the type 2 diabetes treatment 'DWP16001 (SGLT2 inhibitor)' in both monotherapy and combination therapy. Accordingly, it plans to apply for new drug approval from the Ministry of Food and Drug Safety in the first half of this year. This is the first domestically developed new drug of an SGLT2 inhibitor in Korea.